In summary, we found that miR-124-3p derived from hBMSCs could be absorbed by DLBCL cells and inhibit tumor growth both in vivo and in vitro via downregulation of the NFATc1/cMYC pathway (Fig. 7E). Here, MYC is linked to diffuse large B-cell lymphoma.